Medicure enters new agreements for phase 3 coronary artery study

By Elaine Rigoli

Tampa, Fla., Aug. 16 - Medicure, Inc. announced that Duke Clinical Research Institute and Montreal Heart Institute have agreed to lead the upcoming phase 3 Coronary Artery Bypass Graft (CABG) study with MC-1.

The study, titled Mend-CABG II, will enroll up to 3,000 patients at more than 120 sites throughout North America and Europe.

The mechanism of action of MC-1, protecting the heart at the cellular level, is a novel approach to managing ischemic reperfusion injury, and it has shown positive results in two phase 2 studies, officials noted.

"The cardiovascular community will be intently watching the outcome of this phase 3 study, as its result, if positive, could have a significant benefit and lasting impact on how CABG patients are treated," said Robert Harrington, Duke professor of medicine and director of cardiovascular clinical trials, in a news release.

Medicure is a biopharmaceutical company based in Winnipeg, Man.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.